Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Conditions

Prostatic Neoplasms 147Breast Neoplasms 108Lung Neoplasms 92Carcinoma, Non-Small-Cell Lung 77Neoplasm Metastasis 68Glioblastoma 68Brain Neoplasms 64Glioma 59Pancreatic Neoplasms 45Carcinoma, Renal Cell 43Multiple Myeloma 41Squamous Cell Carcinoma of Head and Neck 39Colorectal Neoplasms 38Lymphoma, Large B-Cell, Diffuse 37Neoplasms 34Melanoma 32Lymphoma 32Carcinoma, Hepatocellular 32Urinary Bladder Neoplasms 31Ovarian Neoplasms 29Astrocytoma 28Sarcoma 25Oropharyngeal Neoplasms 24Lymphoma, Follicular 23Central Nervous System Neoplasms 23Rectal Neoplasms 22Uterine Cervical Neoplasms 21Triple Negative Breast Neoplasms 21Mouth Neoplasms 21Lymphoma, Non-Hodgkin 21

Interventions

Nivolumab 20Ipilimumab 10Paclitaxel 7linrodostat 6Standard of Care 6Sirolimus 5Gemcitabine 5Bevacizumab 5temsirolimus 4relatlimab 4Pemetrexed 4Docetaxel 4Carboplatin 4ARRY-334543 4Vorinostat 3Erlotinib Hydrochloride 3Dasatinib 3Cetuximab 3regorafenib 2olaparib 2apatinib 2anlotinib 2abemaciclib 2Trastuzumab 2Surveys and Questionnaires 2Sunitinib 2Sorafenib 2Olanzapine 2N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide 2Magnetic Resonance Spectroscopy 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Advanced Cancer × Magnetic Resonance Spectroscopy × Clear all
NCT01143779 2022-01-04

FLT-PET as an Imaging Biomarker With Temsirolimus, Topotecan, and Bortezomib

M.D. Anderson Cancer Center

Phase 1 Completed
3 enrolled

Advanced Cancer

NCT00610493 2017-12-08

Bevacizumab and Temsirolimus in Patients With Advanced Malignancy

M.D. Anderson Cancer Center

Phase 1 Completed
193 enrolled

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡